Jaren Landen, Ph.D. is a clinical leader with 20 years of global major pharmaceutical experience focused on developing new medicines for patients with unmet medical needs with a passion for Alzheimer’s disease (AD). Jaren has extensive experience with clinical trial design leading all phases of clinical development strategy, regulatory interactions, publications, and business development. Jaren is currently the Head of the Early Alzheimer’s Disease group at Biogen where she provides clinical development expertise for all aspects of the AD portfolio. Jaren joined Biogen in 2017 after a 15 year career at Pfizer. While at Pfizer, Jaren worked in the neuroscience clinical development group spanning across indications including Alzheimer’s disease, Parkinson’s Disease, pain, and stroke. Jaren has run numerous clinical trials in all phases of clinical development with an emphasis on Alzheimer’s disease. While at Pfizer, Jaren designed, implemented, and interpreted the results of several anti-amyloid programs as well as a BACE inhibitor and a gamma secretase inhibitor. Jaren worked on several approved products including varenicline and Lyrica. Jaren did her academic training at Emory University in Neuroscience and teaches graduate Biotechnology at Northeastern University as an adjunct professor.